Edit

Piramal Pharma Solutions

http://www.piramalpharmasolutions.com/

Last activity: 16.09.2026

Active

Categories: CommerceDevelopmentDrugHealthTechLifeManufacturingMedTechProductServiceSupply

We serve our clients through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies, Commercial supply of APIs, and Finished dosage forms. We also offer specialized services like the development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide.
For more information and updates, please visit: www.piramalpharmasolutions.com

Likes

2.21K

Followers

3.32K

Website visits

29.2K /mo.

Mentions

Location: United States, Kentucky, Lexington

Employees: 1001-5000

Founded date: 1988

Twitter

Facebook

Youtube

Investors 2

Date	Name	Website
-	The Carlyl...	carlyle.co...
23.07.2021	BDC	bdc.ca/

Mentions in press and media 23

Date	Title	Description
16.09.2026	Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site	Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. The new plant will provide renewable energy directly to the site through a behind-the...
19.08.2026	Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited	Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a br...
04.08.2026	Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite	Piramal Pharma Solutions has added a new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India, equipped with its own air handling units, nitrogen supply, and control systems. The new suite e...
22.06.2026	Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits	Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. This milestone reflects the Company's long-...
18.05.2026	Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development	Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. Sofdra is the first and only FDA-approved new chemica...
13.05.2026	Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility	The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. This cutting-edge suite will significantly enhance the ...
16.04.2026	Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing	Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to commercialization. Ajinomoto Bio-Pharma S...
14.04.2023	Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market to Touch Valuation of US$ 140.03 Billion by 2031: Astute Analytica	-
04.01.2022	Multiple blockbusters from Gilead, Pfizer, Vertex see (list) price hikes to start 2022	Eisai’s metastatic breast cancer patient portrait campaign “This is MBC” began seven years ago to bring metastatic cancer stories and conversations into the open. Its latest iteration with partner advocacy group METAvivor is called “fearLES...
04.01.2022	UPDATED: US restarts shipments of two mAbs that don't work against Omicron as Merck pills see wider distribution	All the big R&D trends are on display in this new, record-topping list of drug approvals for 2021. Plus one. Add up everything OK’d from CDER and CBER, and you have 61 new drug approvals for last year, topping the 59 OKs that had tied a...
04.01.2022	Indian CDMO Piramal Pharma to up in vitro capabilities at existing site	During a typically quiet holiday break in biotech, Piramal Pharma made some noise, and it’s starting off 2022 with yet another big announcement. The CDMO will invest millions into creating a high-throughput screening ...
04.01.2022	Multiple blockbusters from Gilead, Pfizer, Vertex see (list) price hikes to start 2022	Pfizer pitched some early New Year’s resolutions with Covid-related rules in LinkedIn and Facebook video posts just before the end of the year. Resolution rule number one was a suggestion for those who didn’t have a promise yet for 2022 to ...
04.01.2022	Multiple blockbusters from Gilead, Pfizer, Vertex see (list) price hikes to start 2022	Susan Sweeney spent more than two decades in drug commercialization at Bristol Myers Squibb before moving to Amgen in September 2019, just a few months before the Covid-19 pandemic. Sweeney, now Amgen’s senior VP of global marketing, access...
31.03.2021	Piramal Pharma Solutions picks up Indian peptide API maker in push into oncology, metabolic contract work	Peptide therapeutics have been a hot area for investment in recent years, and contract manufacturing players are ramping up capacity to meet growing demand. India’s Piramal Pharma Solutions, fresh off a major cash ...
31.03.2021	UPDATED: Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died	With blockbuster immunology meds Enbrel and Otezla already in the fold, Amgen has mostly stood pat on infusing new blood into its legacy pipeline. But that success won’t last forever, and Amgen is taking a far-looking bet on a private biote...
31.03.2021	Bausch Health sells off Amoun for $740M; Achilles debuts on Nasdaq with $175.5M IPO	Looking to pay down debt ahead of the big Bausch + Lomb spinoff, Bausch Health CEO Joseph Papa has struck a deal to sell one of its units in Egypt for $740 million. Abu Dhabi-based holding company ADB is handing over the cash for Am...
31.03.2021	UPDATED: Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died	BridgeBio $BBIO is on a roll. At the end of February, they won an approval for their first drug, a therapy used to treat extremely rare cases of molybdenum cofactor deficiency type A. In the middle of the month, there was positive proof-of-...
31.03.2021	UPDATED: Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died	It’s been two weeks on the dot since Mike Nally said he would leave the chief marketing post at Merck, where he was reportedly in the running to replace CEO Ken Frazier, for another leadership opportunity. Now we know where he’s headed. The...
31.03.2021	Piramal Pharma Ltd. To Acquire 100% Stake in Hemmo Pharmaceuticals, a Leading Indian Manufacturer of Peptide APIs
30.03.2021	After pilot project, Takeda inks $500M pact to tap into a Kevan Shokat protégé's covalent small molecule fishing platform	As new technologies open up new avenues toward targets widely considered undruggable by small molecules, Takeda is taking a chance on a low-profile drug discovery player with promises of up to $500 million in biobucks. P...
30.03.2021	Forma sees data 'supporting' sickle cell therapy dosing levels; LianBio teams with Tarsus for eye irritation in China	Looking to make a splash in sickle cell, Forma Therapeutics presented new data they hope can improve their shot at an eventual FDA OK. As part of an ongoing Phase I study, Forma said its FT-4202 program showed enough hemog...
30.03.2021	Novartis dives even deeper into radioligands, notching licensing deal with iTheranostics for multiple compounds	Novartis captured attention last week for its Phase III prostate cancer win with a radioligand therapy it picked up for $2 billion back in 2018. Now, Novartis is doubling down on the field. Novartis will acquire develop...
25.01.2021	Piramal Pharma Solutions Announces Sterile Fill/Finish Program with Theratechnologies Inc. for TH1902 Peptide-drug Conjugate USA - English USA - English USA - English USA - English Italia - Itali...

Piramal Pharma Solutions

Investors 2

Mentions in press and media 23

Reviews 0